RedHill Biopharma (RDHL) Invested Capital (2012 - 2025)

RedHill Biopharma (RDHL) has 14 years of Invested Capital data on file, last reported at $19.0 million in Q4 2025.

• Invested Capital for Q4 2025 came in at $19.0 million, up 159.59% year-over-year; the trailing twelve-month figure through Dec 2025 was $19.0 million (up 159.59% YoY), and the FY2025 annual result was $19.0 million, up 159.59% from the prior year.
• Invested Capital improved to $19.0 million in Q4 2025 per RDHL's latest filing, from -$4.4 million in the prior quarter.
• Over five years, Invested Capital peaked at $113.9 million in Q3 2022 and troughed at -$37.2 million in Q4 2022.
• A 5-year average of $46.0 million and a median of $55.9 million in 2021 frame the typical range for Invested Capital.
• The sharpest annual moves came in 2022 and 2025: Invested Capital plunged 226.87% in 2022, then jumped 159.59% in 2025.
• A 5-year view of Invested Capital shows it stood at $29.4 million in 2021, then sank by 226.87% to -$37.2 million in 2022, then surged by 108.7% to $3.2 million in 2023, then soared by 126.25% to $7.3 million in 2024, then jumped by 159.59% to $19.0 million in 2025.
• Business Quant data shows RDHL's Invested Capital at $19.0 million in Q4 2025, -$4.4 million in Q2 2025, and $7.3 million in Q4 2024.